012). On univariate analysis of our data, several Sotrastaurin solubility dmso clinical factors including AFP, tumor multiplicity, tumor size, vascular invasion and TNM stage showed prognostic significance for both OS and TTR (Table 2). Then, significant clinical

factors were used for further multivariate analysis. Tumor number, tumor size and TNM stage were demonstrated to be related with OS (P < 0.001, <0.001 and =0.004) and TTR (P = 0.001, <0.001 and =0.015), respectively. While vascular invasion was an independent predictor for OS (P = 0.037). Furthermore, combination of intratumoral IL-17RE and IL-17 densities showed higher predictive value on outcome of HCC patients by multivariate (Table 2) and predictive accuracy by ROC analysis (Figure 3) than either factor alone. To analyze the prognostic Napabucasin capacity of these biomarkers for early recurrence (metastasis after surgery ≤24 months) TSA HDAC and late recurrence (new primary lesion after surgery

>24 months) [4], Kaplan-Meier method was performed. Combination of intratumoral IL-17RE and IL-17 densities were found to be more likely to suffer from tumor early and late recurrences by univariate and multivariate analysis (Table 3). In addition, peritumoral IL-17RE density also showed the predictive power in OS and TTR (Figure 2). Figure 3 Receiver operating characteristic analysis based on (a) overall survival and (b) time to recurrence of 300 HCC patients. Peritumoral IL-17RE expression (AUCTTR = 0.646, P < 0.001; AUCOS = 0.688, p < 0.001), intratumoral IL-17 expression (AUCTTR = 0.611, P < 0.001; AUCOS = 0.581, p = 0.023), peritumoral IL-17 expression (AUCTTR = 0.476, P = 0.474; AUCOS = 0.477, p = 0.509), intratumoral IL-17RE expression (AUCTTR = 0.646, P = 0.005; AUCOS = 0.637, p < 0.001), combination of intratumoral IL-17 and IL-17RE expression (AUCTTR = 0.650, P <0.001; AUCOS = 0.681, p < 0.001), AFP (AUCTTR = 0.572,

P =0.031; AUCOS = 0.565, p = 0.066), tumor number (AUCTTR = 0.545, P =0.178; AUCOS = 0.549, p = 0.167), vascular invasion (AUCTTR = 0.557, P =0.087; AUCOS = 0.610, p = 0.002), tumor size (AUCTTR = 0.585, P =0.011; AUCOS = 0.659, p < 0.001), TNM stage (AUCTTR = 0.571, P =0.033; AUCOS = 0.612, p = 0.002). Table 3 Prognostic factors for early and late recurrence Factor Early recurrence Late recurrence   Univeriate SPTLC1 Multivariate Univeriate Multivariate   P HR (95% CI) P P HR (95% CI) P AFP(ng/ml)(≤20 v >20) 0.018 1.457(1.012-2.098) 0.043 NS   NA Tumor size(cm) (≤5.0 v >5.0) <0.001 1.799(1.272-2.544) 0.001 NS   NA Vascular invasion(yes v no) <0.001 1.472(1.032-2.101) 0.033 NS   NA TNM stage (I v II- III) 0.001 1.423(1.003-2.020) 0.048 NS   NA Peritumoral density (low v high) IL-17RE <0.001 1.604(1.129-2.280) 0.008 0.001 2.148(1.158-3.986) 0.015 Intratumoral density (low v high) IL-17RE 0.001   NS 0.007   NS Il-17 0.004   NS 0.034   NS Combination of IL-17RE &IL-17 <0.001 1.430(1.227-1.666) <0.001 <0.001 1.458(1.093-1.947) 0.